Trial | NCT01841086  Report issue

Title

Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation
A Randomized, Open-label, Single Dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Sarpogrelate HCl CR Tablets Compared With Sarpogrelate HCl IR Tablets in Healthy Male Subjects

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    sarpogrelate ...

  • Study Participants

    50
The purpose of this study is to evaluate the pharmacokinetics of sarpogrelate controlled-release formulation (CR) in comparison to immediate-release formulation (IR) and Food effect on the pharmacokinetics of sarpogrelate CR.
Study Started
Sep 30
2011
Primary Completion
Nov 30
2011
Study Completion
Dec 31
2011
Last Update
Apr 26
2013
Estimate

Drug Anplag

Sarpogrelate HCl 300mg once a day or 100mg three times a day

  • Other names: UI03SPG300CT

Drug UI03SPG300CT

Sarpogrelate HCl 300mg once a day or 100mg three times a day

Anplag Active Comparator

Sarpogrelate HCl 300mg once a day or 100mg three times a day

UI03SPG300CT Experimental

Sarpogrelate HCl 300mg once a day or 100mg three times a day

Criteria 

Inclusion Criteria:

20 to 55 years of healthy volunteers

Exclusion Criteria:

Hypersensitivity Reaction about Sarpogrelate HCl or other antiplatelets
No Results Posted